Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment